How Blockchain Can Increase Accessibility to Stem Cell Therapy

How-Blockchain-Can-Increase-Accessibility-To-Stem-Cell-Therapy-nuv2rsxjt44hfzhay6m2muc596iyxa6z2hckijv6ei

Photo courtesy of BTCManager

The revolution has arrived. Believe it or not, we are living in a world where artificial intelligence, virtual reality, and stem cell therapies are no longer concepts of science fiction, but are realities of our everyday life. While the development of these things may appear to be in their infancy, it’s undoubtedly true that they each hold a unique opportunity for science to unlock cures to diseases like ALS, Sickle Cell disease, Alzheimer’s and Duchenne’s Muscular Dystrophy.

What is equally true however, is despite the fact that these opportunities are on the horizon, on a global scale there are still significant barriers to accessing clinical trials and quality medical care.

So how do we address this?

Well, according to a company called Stem Cell Project – we need to get creative.

This new Japan-based company set out to create the blockchain-enabled Virtual Clinic, fully equipped with AI technology, diagnostic tools, and its own native currency, the Stem Cell Coin.

 Issues with Modern Healthcare

Modern healthcare has developed rapidly in the past few decades, but is not without its drawbacks. For many people there’s a degree of difficulty in gaining access to qualified specialists. When you consider basic factors like distance and skill shortage, or larger issues like the lack of universal healthcare, it means the average person is unable to afford the high cost of preventative medical treatments, leading to more than 45,000 deaths per year in the United States alone.

In many first-world countries, birth rates have declined over the decades whilst the general population has continued to age. Not only has this has increased the need for specialists in fields treating diseases of aging, like Cancer and Alzheimer’s, but it also means we need to accelerate our efforts to keep up with the growing population.

Using Blockchain to Access Health Records

While many hear the word blockchain and think of cryptocurrencies, it also allows for an ultra-secure means by which patients can interact with healthcare professionals without worrying if malicious third-parties can access their most sensitive personal data. It is for this reason that Stem Cell Project decided to use the groundbreaking technology in their Virtual Clinic.

“Patients are increasingly aware of how their data is being used and who is allowed to access it,” explained Stem Cell Project’s founder Shuji Yamaguchi in a news release. “We therefore wanted to find a solution that was highly secure. Having a patient’s trust is, in many ways, the first step to mass adoption for Stem Cell Coin.”

Beyond that, the platform also ensures patients have access to a decentralized and unchangeable health record. Something which to date has never been fully implemented by a large-scale healthcare organization such as the one backing Stem Cell Project.

Opening the Path to Healthcare Equality

As Stem Cell Coin’s vision continues to be rolled out, a number of complementary applications will also be developed to support the Virtual Clinic. Among these, digital initiatives such as pathological and diagnostic imaging systems have the potential to further build upon the notion of a decentralized, universally-accessible healthcare ecosystem.  Moreover, the ability to pay for stem cell treatment via Stem Cell Coin will allow people to pay and travel for therapy regardless of whether their country exerts strict capital controls. The best example of this is China, where even its wealthy citizens are unable to travel to places like the United States of America and Europe for treatment, as the current cost for stem cell therapy ($10,000 – $50,000) exceeds the limits imposed by their government on how much Yuan can be taken abroad.

Counterfeit drugs and treatments could become easier to spot:

Based on reports from the World Health Organization (WHO), the value of the counterfeit drug market is $200 billion annually. In fact, they estimate 80% of the counterfeit drugs that are consumed in the United States come from overseas. Furthermore – they believe that 16% of counterfeit drugs contain the wrong ingredients, and 17% contain the wrong levels of necessarily ingredients. Not only does this undermine the research and scientists, who are actively looking for treatments by following an established protocol, but the financial burden families and patients are enduring to have access to these drugs is considerably high – especially given that WHO reports that 30% of the counterfeit drugs that are available don’t contain any active ingredients whatsoever. A blockchain-based system would ensure a chain-of-custody log, tracking each step of the supply chain at the individual drug/product level.

Results from clinical trials could become more transparent:

It is estimated that 50% of clinical trials go unreported, and investigators often fail to share their study results. This has created crucial safety issues for patients and knowledge gaps for healthcare stakeholders and health policymakers. Some say, blockchain-enabled, time-stamped immutable records of clinical trials, protocols and results could address the issues of fraudulent outcome reporting, data snooping and selective reporting, thereby reducing the incidence of fraud and error in clinical trial records. Furthermore, blockchain-based systems could help drive unprecedented collaboration between participants and researchers for innovative research projects.

 As new projects such as Stem Cell Coin are able to increase access to regenerative medicine, not only will distance or income cease to determine health outcomes, but we might even be able to address other issues plaguing the healthcare industry.

 

 

 

See You Next Week: 2014 Stem Cell Meeting on the Mesa

Next week marks the fourth annual Stem Cell Meeting on the Mesa (SCMOM) Partnering Forum in La Jolla, California and CIRM , one of the main organizers, hopes to see you there.

SCMOM

SCMOM is the first and only meeting organized specifically for the regenerative medicine and cell therapy sectors. The meeting’s unique Partnering Forum brings together a network of companies—including large pharma, investors, research institutes, government agencies and philanthropies seeking opportunities to expand key relationships in the field. The meeting will feature presentations by 50 leading companies in the fields of cell therapy, gene therapy and tissue engineering.

Co-founded by CIRM and the Alliance for Regenerative Medicine (ARM), SCMOM has since grown both in participants and in quality. As Geoff MacKay, President and CEO of Organogenesis, Inc. and ARM’s Chairman, stated in a recent news release:

“This year the Partnering Forum has expanded to include an emphasis not only on cell therapies, but also gene and gene-modified cell therapy technologies. This, like the recent formation of ARM’s Gene Therapy Section, is a natural progression for the meeting as the advanced therapies sector expands.”

This year CIRM President and CEO Dr. C. Randal Mills, as well as Senior Vice President, Research & Development Dr. Ellen Feigal will be speaking to attendees. In addition, 12 CIRM grantees will be among the distinguished speakers, including Drs. Jill Helms, Don Kohn and Clive Svendsen, as well as leaders from Capricor, Asterias, ViaCyte, Sangamo Biosciences and others.

CIRM has made tremendous progress advancing stem cell therapies to patients and expects to have ten approved clinical trials by the end of 2014. The trials which span a variety of therapeutic areas using several therapeutic strategies such as cell therapy, monoclonal antibodies and small molecules are increasingly being partnered with major industry players. CIRM still has more than $1 billion to invest and is interested in co-funding with industry and investors—don’t miss the chance to strike the next partnership at SCMOM next week.

For more details and to view the agenda, please visit: http://stemcellmeetingonthemesa.com/